Cara Therapeutics ( CARA ) announced that it had achieved positive phase 3 results from its phase 3 KALM-1 study treating hemodialysis patients with CKD associated pruritus using KORSUVA injection. There...
Cara Therapeutics Inc.
Cara Therapeutics is a clinical-stage biotechnology company located in Stamford, CT focused on developing and commercializing new chemical entities designed to fundamentally change the way acute pain, chronic pain and pruritus are managed.
Doctor
1d
5d
1m
6m
1y
Max
Cara Therapeutics Inc. News
11 Jun
Cara's Second Half Catalyst Has The Potential To Change The Scope Of The Biotech Forever
Investment Thesis Cara Therapeutics ( CARA ) recently reported top-line results of its Phase III KALM-1 U.S. clinical study of KORSUVA Injection in Hemodialysis Patients with moderate-to-severe Pruritus....
07 Jun
Cara Therapeutics (CARA) Presents At Jefferies 2019 Healthcare Conference - Slideshow
The following slide deck was published by Cara Therapeutics, Inc. in conjunction with this Read more …
A pivotal trial for the company's lead candidate was an unequivocal success.
STAMFORD, Conn., May 31, 2019 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a.
Cara (CARA) reports positive top-line data from phase III study of Korsuva injection in hemodialysis patients with moderate-to-severe chronic kidney disease-related pruritus.
surged Wednesday after the biopharmaceutical company reported positive results for a Phase 3 trial of a clinical study for its medication, Korsuva, an injection for patients with kidney disease-related...
29 May
Stocks making the biggest moves midday: Canada Goose, Capri Holdings, General Mills & more
Canada Goose GOOS-CA — Canada Goose shares plummeted more than 26% after the company issued disappointing full-year revenue guidance . Capri Holdings CPRI — The parent company of Michael Kors fell more...
Small-cap biotech Cara Therapeutics Inc (NASDAQ: CARA ) is trading to its highest level since early April after it released the results of a Phase 3 trial for its lead candidate Korsuva. What Happened...
The biotech reported great late-stage clinical results for its lead drug candidate.
About Cara Therapeutics Inc.
We aim to achieve this by developing new products that selectively target the body’s peripheral kappa opioid receptors. Cara is developing a novel and proprietary class of product candidates that target the body’s peripheral nervous system and have demonstrated initial efficacy in patients with moderate-to-severe pain and pruritus (itch) without inducing many of the undesirable side effects typically associated with currently available pain and itch therapeutics.
Cara’s most advanced compound, CR845, is currently undergoing clinical testing for acute pain, chronic pain and uremic pruritus (itch). In multiple randomized, double-blind, placebo-controlled Phase 2 trials in patients undergoing laparoscopic hysterectomy or bunionectomy procedures, I.V. CR845 treatment resulted in statistically significant reductions in both pain intensity and opioid-related side effects.
With well over 1000 subjects dosed to date, CR845 was found to be well tolerated, without incurring the dysphoric and psychotomimetic side effects that have been reported with centrally acting (CNS-active) kappa opioid receptor agonists.
Team
Michael E. Lewis
Chief Scientific Advisor
Harrison M. Bains
Director
$ 2.85
-5.32%
Open:
3.03
High:
3.03
Low:
2.85
Market cap:
769.989 M
Symbol:
CARA
Contact info
Phone:
(203) 406-3700
Address:
107 Elm St, Stamford, CT 06902, USA
